Alliancebernstein L.P. decreased its stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 7.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,500 shares of the specialty pharmaceutical company’s stock after selling 1,100 shares during the period. Alliancebernstein L.P. owned about 0.10% of Eagle Pharmaceuticals worth $1,203,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. State Board of Administration of Florida Retirement System raised its stake in shares of Eagle Pharmaceuticals by 2.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 5,305 shares of the specialty pharmaceutical company’s stock valued at $421,000 after buying an additional 150 shares during the period. Comerica Bank raised its stake in Eagle Pharmaceuticals by 5.2% in the fourth quarter. Comerica Bank now owns 8,445 shares of the specialty pharmaceutical company’s stock worth $585,000 after buying an additional 415 shares during the period. FMR LLC bought a new stake in Eagle Pharmaceuticals during the fourth quarter worth $7,300,000. Thrivent Financial for Lutherans raised its stake in Eagle Pharmaceuticals by 1.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $333,000 after buying an additional 60 shares during the period. Finally, Norges Bank bought a new stake in Eagle Pharmaceuticals during the fourth quarter worth $5,634,000.
Shares of Eagle Pharmaceuticals, Inc. (EGRX) opened at 50.48 on Friday. The firm has a 50-day moving average price of $74.77 and a 200-day moving average price of $77.39. The stock has a market cap of $772.24 million, a price-to-earnings ratio of 7.93 and a beta of 1.48. Eagle Pharmaceuticals, Inc. has a 52 week low of $42.33 and a 52 week high of $97.15.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.44 by $0.02. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The firm had revenue of $76.80 million during the quarter, compared to analyst estimates of $70.10 million. During the same quarter last year, the company posted ($0.06) EPS. The company’s revenue was up 159.5% on a year-over-year basis. On average, equities analysts anticipate that Eagle Pharmaceuticals, Inc. will post $3.57 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Stake Reduced by Alliancebernstein L.P.” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/07/29/eagle-pharmaceuticals-inc-nasdaqegrx-stake-reduced-by-alliancebernstein-l-p.html.
EGRX has been the subject of a number of recent research reports. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Royal Bank Of Canada set a $86.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, April 24th. Piper Jaffray Companies set a $118.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $84.00.
In other Eagle Pharmaceuticals news, CFO Pete A. Meyers acquired 350 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was bought at an average price of $71.49 per share, with a total value of $25,021.50. Following the purchase, the chief financial officer now owns 350 shares in the company, valued at $25,021.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have purchased 805 shares of company stock valued at $61,790. Insiders own 19.50% of the company’s stock.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
